• 1
    Jessup M, Abraham WT, Casey DE, et al.2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. April 2009;119:19772016.
  • 2
    Dickstein K, Cohen-Solal A, Filippatos G, et al.ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. October 2008;29:23882442.
  • 3
    McMurray JJ, Adamopoulos S, Anker SD, et al.ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. July 2012;33:17871847.
  • 4
    Pitt B. Aldosterone blockade in patients with systolic left ventricular dysfunction. Circulation. October 2003;108:17901794.
  • 5
    Greenberg B, Zannad F, Pitt B. Role of aldosterone blockade for treatment of heart failure and post-acute myocardial infarction. Am J Cardiol. May 2006;97:34F40F.
  • 6
    Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 ed. Chichester: The Cochrane Collaboration; 2008.
  • 7
    Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. October 2005;331:897900.
  • 8
    Spiegelhalter D, Abrams K, Myles J. Bayesian Approaches to Clinical Trials and Health-Care Evaluation. Statistics in Practice. Chichester, UK: John Wiley & Sons Ltd; 2004.
  • 9
    MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. June 1999;353:20012007.
  • 10
    AIRE Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. October 1993;342:821828.
  • 11
    McMurray JJ, Ostergren J, Swedberg K, et al.Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. September 2003;362:767771.
  • 12
    Zannad F, McMurray JJ, Krum H, et al.Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. January 2011;364:1121.
  • 13
    Kuenzli A, Bucher HC, Anand I, et al.Meta-analysis of combined therapy with angiotensin receptor antagonists versus ACE inhibitors alone in patients with heart failure. PLoS ONE. 2010;5:e9946.
  • 14
    McMurray JJ, Pitt B, Latini R, et al.Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. May 2008;1:1724.
  • 15
    Boccanelli A, Mureddu GF, Cacciatore G, et al.Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results. Eur J Heart Fail. January 2009;11:6876.
  • 16
    Solomon SD, Hee Shin S, Shah A, et al.Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction. Eur Heart J. May 2011;32:12271234.
  • 17
    Cice G, Di Benedetto A, D’Isa S, et al.Effects of telmisartan added to angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial. J Am Coll Cardiol. November 2010;56:17011708.
  • 18
    Cicoira M, Zanolla L, Rossi A, et al.Long-term, dose-dependent effects of spironolactone on left ventricular function and exercise tolerance in patients with chronic heart failure. J Am Coll Cardiol. July 2002;40:304310.
  • 19
    Pitt B, Remme W, Zannad F, et al.Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. April 2003;348:13091321.
  • 20
    Gao X, Peng L, Adhikari CM, et al.Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure. J Card Fail. April 2007;13:170177.
  • 21
    Pitt B, Zannad F, Remme WJ, et al.The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. September 1999;341:709717.
  • 22
    McKelvie RS, Yusuf S, Pericak D, et al.Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation. September 1999;100:10561064.
  • 23
    Udelson JE, Feldman AM, Greenberg B, et al.Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction. Circ Heart Fail. May 2010;3:347353.
  • 24
    Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. December 2001;345:16671675.
  • 25
    Pfeffer MA, McMurray JJ, Velazquez EJ, et al.Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. November 2003;349:18931906.
  • 26
    Weir RA, Mark PB, Petrie CJ, et al.Left ventricular remodeling after acute myocardial infarction: does eplerenone have an effect?Am Heart J. June 2009;157:10881096.
  • 27
    Yasumura Y, Miyatake K, Okamoto H, et al.Rationale for the use of combination angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker therapy in heart failure. Circ J. April 2004;68:361366.